 Connection
Breelyn Wilky to Molecular Targeted Therapy
This is a "connection" page, showing publications Breelyn Wilky has written about Molecular Targeted Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.765 |
|
|
|
-
Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer. 2019 08; 43(4):300-307.
Score: 0.470
-
Florou V, Wilky BA. Current and Future Directions for Angiosarcoma Therapy. Curr Treat Options Oncol. 2018 03 08; 19(3):14.
Score: 0.430
-
Wilky BA, Kim C, McCarty G, Montgomery EA, Kammers K, DeVine LR, Cole RN, Raman V, Loeb DM. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. Oncogene. 2016 05 19; 35(20):2574-83.
Score: 0.362
-
Fontebasso AM, Rytlewski JD, Blay JY, Gladdy RA, Wilky BA. Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors. Hematol Oncol Clin North Am. 2026 10; 40(5):875-894.
Score: 0.195
-
Dao D, Kozak K, Mailhot A, Tutton S, Rutkowski P, Wilky BA. Desmoid Tumors-Biology-Driven Management and Treatment Selection. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520026.
Score: 0.189
-
Agulnik M, Wilky BA, Thorpe SW, Zuckerman LM. Chondrosarcoma: Clinical behavior, molecular mechanisms, and emerging therapeutic strategies. Crit Rev Oncol Hematol. 2026 Feb; 218:105075.
Score: 0.046
-
Florou V, Wilky BA, Trent JC. Latest advances in adult gastrointestinal stromal tumors. Future Oncol. 2017 Oct; 13(24):2183-2193.
Score: 0.026
-
Tan Y, Trent JC, Wilky BA, Kerr DA, Rosenberg AE. Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Ther. 2017 Mar; 24(3):130-133.
Score: 0.025
-
Tinoco G, Wilky BA, Paz-Mejia A, Rosenberg A, Trent JC. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase. Am Soc Clin Oncol Educ Book. 2015; e648-55.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|